Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine

The nucleoside analog azacitidine (AZA) is used in the treatment of myelodysplastic syndromes (MDS), but 30–40% of patients fail to respond or relapse after treatment. Hence, to identify new molecular alterations that allow for identification of patients unlikely to respond to AZA could impact the u...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Valencia, A, Masala, E, Rossi, A, Martino, A, Sanna, A, Buchi, F, Canzian, F, Cilloni, D, Gaidano, V, Voso, M T, Kosmider, O, Fontenay, M, Gozzini, A, Bosi, A, Santini, V
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 2014
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3948159/
https://ncbi.nlm.nih.gov/pubmed/24192812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2013.330
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia